L-R- Lee Hong-won, KRIBB’s director of bio-innovation business; YD Life Science CEO Lee Jin-woo
YD Life Science has signed a technology transfer agreement with Korea Research Institute of Bioscience & Biotechnology (KRIBB) to gain the latter’s anti-cancer gene therapy using CYB5R3, a new cancer inhibitor. According to the agreement, YD Life science will pay 2.5 billion won ($2.1 million) to KRIBB for the substance.
The KRIBB team, led by Professor Won Mi-sun, has developed the novel cancer inhibitor CYB5R3 gene as a candidate gene therapy agent. The team has produced excellent antitumor effects by controlling cancer metabolism, and cancer microenvironment in an animal experiment focused on lung and colorectal cancer.
The team expects that the candidate will expand its indication to various cancer, including gastric, liver, prostate, pancreatic cancer and brain tumors.
The researchers have already registered related patents in Korea and three European countries U.K., France and Germany and are awaiting approval in the U.S. and China.
